A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506791-27-00

Acronym

NOPRODPAPUH3001

Enrollment

Registered

2024-03-13

Start date

2022-04-22

Completion date

Unknown

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Brief summary

Frequency of treatment-emergent adverse events (AEs), treatment-emergent AEs leading to discontinuation, serious adverse events (SAEs), and/or deaths from baseline until End-of-Study (EOS)

Interventions

DRUGJNJ-68150420

DRUGOpsumit 10 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Frequency of treatment-emergent adverse events (AEs), treatment-emergent AEs leading to discontinuation, serious adverse events (SAEs), and/or deaths from baseline until End-of-Study (EOS)	—

Countries

Bulgaria, Hungary, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026